5375 Medpace Way
About CinRx Pharma
CinRx Pharma is a biopharmaceutical company developing novel therapeutics that address substantial unmet medical needs across diverse disease indications. CinRx’s product candidate portfolio includes innovative and disruptive new molecular entities (NMEs) with novel drug delivery techniques.
To advance its growing R&D pipeline, the Company applies industry-leading formulation, preclinical, and CMC expertise in conjunction with clinical development services of Medpace, Inc, a leading global contract research organization (CRO). Led by CEO Jonathan Isaacsohn, MD, FACC, CinRx’s team possesses unparalleled expertise in pharmaceutical R&D, focused expedited clinical development for innovative therapies.
Co-Founder & Co-Founder & CEO: Jonathan Isaacsohn, MD, FACC
Co-Founder & COO: Catherine Pearce, MBA, DHSc
Co-Founder & CSO: Piyush Patel, PhD
Co-Founder & CMO: Brian Murphy, MD, MPH, FIDSA
Please click here for CinRX's pipeline
Please click here for CinRX's job opportunities.
3 articles with CinRx Pharma
A large part of the funding will go to the research and development of CIN-107 as it has shown the potential to treat primary aldosteronism and treatment-resistant hypertension.
CinFina Pharma, LLC. announced that it has signed an agreement with Janssen Sciences Ireland Unlimited Company, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to acquire exclusive global rights to GDF-15 and PYY analogs and GLP-1/GDF-15 and GLP/PYY dual agonists.
The Series B follows a $26 million Series A that closed at the end of 2015.